Label Change Proposal From GPhA, PhRMA Makes FDA Responsible For Timing
This article was originally published in The Pink Sheet Daily
Executive Summary
“Expedited Agency Review” idea would require an FDA review of proposed safety-related labeling changes before they are made and end the CBE-0 system brand companies already use and generics could be required to adopt.
You may also be interested in...
US FDA May Ask Congress For More Resources After Withdrawing Generic Label Reg
Label updates for older generics are still planned, Commissioner Gottlieb says, but will depend more on sponsor collaboration as well as additional resources and authorities from Congress.
Will CBO Score CREATE Momentum For Generic Bill's Passage?
Strong savings estimate – and brand pharma's need to have pay-fors for its own legislative priorities – could finally get bill allowing generic companies to sue brand sponsors for access to samples.
Will CBO Score CREATE Momentum For Generic Bill's Passage?
Strong savings estimate – and brand pharma's need to have pay-fors for its own legislative priorities – could finally get bill allowing generic companies to sue brand sponsors for access to samples.